Evidence map›Paper›PMID 28659717›Full record

ArticleClinical Medicine Insights. Oncology2017

Accuracy of [

Finbar Slevin, Ekin Ermiş, Sriram Vaidyanathan, Mehmet Sen, Andrew F Scarsbrook, Robin Jd Prestwich

Open access · goldAbstract read
In one paragraph

Article in Clinical Medicine Insights. Oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Finbar SlevinDepartment of Clinical Oncology, Yorkshire Cancer Centre, Leeds, UK.
Ekin ErmişDepartment of Clinical Oncology, Yorkshire Cancer Centre, Leeds, UK.
Sriram VaidyanathanDepartment of Radiology, Yorkshire Cancer Centre, Leeds, UK.
Mehmet SenDepartment of Clinical Oncology, Yorkshire Cancer Centre, Leeds, UK.
Andrew F ScarsbrookDepartment of Radiology, Yorkshire Cancer Centre, Leeds, UK.
Robin Jd PrestwichDepartment of Clinical Oncology, Yorkshire Cancer Centre, Leeds, UK.
Yorkshire Cancer Research · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe accuracy of response assessment positron emission tomography (PET)-computed tomography (CT) following radiotherapy with or without chemotherapy for laryngeal/hypopharyngeal squamous cell carcinoma is uncertain.

methodsIn all, 35 patients with laryngeal or hypopharyngeal squamous cell carcinoma who were treated between 2009 and 2014 with (chemo)radiotherapy were identified. The accuracy of response assessment PET-CT was made by correlation with clinical follow-up and pathological findings.

resultsOf the 35 patients, 20 (57%) had an overall complete metabolic response. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for response assessment [18Fluorine]-fluoro-2-deoxy-d-glucose (FDG) PET-CT for primary and nodal sites, respectively, were 100%, 73%, 46%, and 100% and 83%, 95%, 83%, and 95%.

conclusionsResponse assessment FDG PET-CT following (chemo)radiotherapy for laryngeal and hypopharyngeal carcinomas has a high NPV for both primary site and lymph nodes and can be used to guide treatment decisions. The PPV of residual FDG uptake at the primary tumour site is limited and requires examination and biopsy confirmation.

Indexed as

cancerhypopharynxLarynxPET-CTradiotherapy

Identifiers

PMID28659717
PMCPMC5476423
OpenAlexW2626847394

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.